Advertisement
Advertisement

FATE

FATE logo

Fate Therapeutics, Inc.

1.11
USD
Sponsored
+0.09
+9.41%
Jan 07, 15:59 UTC -5
Closed
exchange

Pre-Market

1.10

-0.01
-0.45%

FATE Earnings Reports

Positive Surprise Ratio

FATE beat 22 of 40 last estimates.

55%

Next Report

Date of Next Report
Mar 03, 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.21M
/
-$0.27
Implied change from Q3 25 (Revenue/ EPS)
-30.52%
/
--
Implied change from Q4 24 (Revenue/ EPS)
-34.96%
/
-38.64%

Fate Therapeutics, Inc. earnings per share and revenue

On Nov 13, 2025, FATE reported earnings of -0.27 USD per share (EPS) for Q3 25, beating the estimate of -0.29 USD, resulting in a 9.06% surprise. Revenue reached 1.74 million, compared to an expected 1.57 million, with a 11.20% difference. The market reacted with a -4.59% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of -0.27 USD, with revenue projected to reach 1.21 million USD, implying an increase of 0.00% EPS, and decrease of -30.52% in Revenue from the last quarter.
FAQ
For Q3 2025, Fate Therapeutics, Inc. reported EPS of -$0.27, beating estimates by 9.06%, and revenue of $1.74M, 11.2% above expectations.
The stock price moved down -4.59%, changed from $1.04 before the earnings release to $0.99 the day after.
The next earning report is scheduled for Mar 03, 2026.
Based on 15 analysts, Fate Therapeutics, Inc. is expected to report EPS of -$0.27 and revenue of $1.21M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement